Chetan Bansal

I'll research this attorney before drafting.

Chetan R. Bansal — Patent Litigation Practice Summary

Focus areas. Bansal is Of Counsel in Paul Hastings' Litigation Department in Washington, D.C., with a practice concentrated on patent office proceedings, district court litigation, and Federal Circuit appeals. His engineering background (electrical engineering) aligns with his firm bio's stated experience in computer networks and telecommunications, and his PTAB docket includes semiconductor, NFC/wireless-charging, and networking matters for clients such as Samsung, Google, NVIDIA, and ProMOS. He also works across life sciences and medical technology — COVID-19 vaccine mRNA patents (BioNTech), small-molecule antiemetic drug patents (Helsinn), neuromodulation (Medtronic/Axonics), and orthopedic devices (Zimmer Biomet) — so his subject-matter range is broader than a single technology vertical.

Side preference. The tracked appearance data is small and one-sided: two entries, both on the defendant/patent-owner side, both as back-up counsel. That undersells his actual posture — Paul Hastings' own bio states he has represented both petitioners and patent owners in post-grant proceedings, which is consistent with a PTAB-centric practice where counsel frequently appears on either side. The defensible read is a defense-oriented practice that also files offensive IPR petitions.

Firm context. He is at Paul Hastings (current firm), in the D.C. office, listed as Of Counsel. His bio notes only that, before joining Paul Hastings, he was a student associate in the IP practice of an international law firm; no other prior firm is identified in the sources reviewed.

Notable matters and PTAB experience. PTAB work is the core of his practice — the firm bio describes "hundreds" of post-grant proceedings (IPRs, PGRs, CBMs, and reexaminations), with substantial brief-writing, expert depositions, and first- and second-chair oral argument experience. Prominent examples: BioNTech SE v. ModernaTX (IPR2023-01358/-01359), where the PTAB found all challenged claims of two Moderna COVID-19 vaccine patents unpatentable on March 5, 2025 — the Paul Hastings team, including Bansal, was named an American Lawyer "Litigator of the Week" runner-up; Moderna has appealed. He also appears in Axonics, Inc. v. Medtronic, Inc. (representing Medtronic in IPRs and appeals), Samsung v. NuCurrent, nVidia v. Samsung, Google v. Silver State, and Exactech v. Zimmer Biomet. On the tracked case, Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A., Paul Hastings represents Helsinn (patent owner/defendant) in a multi-petition IPR campaign over Helsinn's Akynzeo® (netupitant/palonosetron) patents; institution decisions have begun issuing. He argued the Federal Circuit appeal in EIS GmbH v. Novoluto GmbH, No. 21-02215 (Fed. Cir. 2023), where the court summarily affirmed the PTAB's decisions upholding the challenged patent claims — an adverse outcome for his client.

Bar / education. Firm bio: J.D., George Washington University Law School (one version of the bio states 2014 with high honors; other firm and Best Lawyers listings state 2015); B.S., Electrical Engineering, University of Maryland, College Park, cum laude (2007). He has been recognized in Best Lawyers: Ones to Watch for Litigation–Patent and Litigation–Intellectual Property since 2024. A specific state bar admission is not clearly documented in the sources reviewed, and at least one PTAB filing lists him under limited recognition rather than a USPTO registration number — that detail should be confirmed with the firm before being relied on.